Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

What’s Going On With PDD Holdings Stock?

PDD Holdings Inc. (NASDAQ: PDD) shares are trading higher Thursday on continued upward momentum. Here's a look at what's going on:
byErica Kollmann
November 30, 2023
1 minute read
Total
0
Shares
0
0
0
0
0
0

PDD Holdings Inc. (NASDAQ:PDD) shares are trading higher Thursday on continued upward momentum. Here’s a look at what’s going on:

What To Know:

PDD Holdings released a blowout third-quarter earnings report Tuesday with quarterly earnings and revenue more than 25% above analyst forecasts and record net income and sales figures.

The stock jumped more than 18% Tuesday as investors digested the financial results, and PDD shares have gained more than 23% over the last five days. The stock reached a new 52-week high of $145.94 on Thursday. 

PDD is trading on above-average volume with more than 6 million shares already traded in the session. According to data from Benzinga Pro, the stock’s 100-day average volume is 9.108 million shares.

According to data from Benzinga Pro, shares of PDD are trading well above the stock’s 50-day moving average of $107.06 and remain near its new 52-week high of $145.94.

Related News: MicroStrategy Adds More Bitcoin: What’s Going On With The Stock?

PDD Price Action: According to Benzinga Pro, PDD Holdings shares are up by 2.3% at $144.93 at the time of publication.

Image: Mohamed Hassan from Pixabay

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Why Autodesk Stock Is Sliding Today

By Adam Eckert
April 17, 9:15 AM
Autodesk said late Tuesday that it's unable to file its annual report for the year ended Jan. 31, 2024, within the 15-day extension period. Accordingly, the company expects to receive a Nasdaq notice informing the company that it is not in compliance with the timely filing requirement for continued listing under Nasdaq rules.

ADSK

Read More

Gilead’s Kite Announced Time to CAR T-cell Therapy May Impact Outcomes for Patients With Relapsed/Refractory Large B-cell Lymphoma in New CIBMTR Analysis at ASH 2022

By Charles Gross
December 11, 11:25 AM
Kite, a Gilead Company (Nasdaq: GILD), today announced results from one of the largest real-world analyses of patients who received CAR T-cell therapy assessing the impact of time from leukapheresis to infusion ("vein-to-vein" time) for Yescarta® (axicabtagene ciloleucel) in adult patients with relapsed or refractory (R/R

GILD